Dec 14, 2022 / 01:30PM GMT
Operator
Good morning, and welcome to the Passage Bio Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
At this time, I'd like to turn it over to Stuart Henderson, Vice President of Corporate Development and Investor Relations. Stuart, please proceed.
Stuart M. Henderson - Passage Bio, Inc. - VP of Corporate Development & IR
Thank you, operator, and good morning, everyone. Today, we will review interim results from the global Imagine-1 Phase 1/2 clinical trial with PBGM01 in infantile gangliosidosis. Please refer to the press release issued earlier and the slides that we will be using on today's call on the Investors view section of the Passage Bio website.
Before we begin, I'd like to remind you that our presentation this morning will contain forward-looking statements based on our current expectations and beliefs of future events as of today. These statements are subject to a number of risks and uncertainties, including those risk factors from our latest 10-Q that could cause
Passage Bio Inc PBGM01 Interim Clinical Data From Cohorts 1-3 of Imagine-1 Call Transcript
Dec 14, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers